A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine

Documents similaires

• Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions
  par: Paolo Mannelli
  Publié: (2024)
• Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review
  par: Emmert Roberts, et autres
  Publié: (2026)
• Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
  par: Gary J. Young, et autres
  Publié: (2024)
• Dose‐specific clinical outcomes in patients with opioid use disorder treated with 24–32 mg/day of buprenorphine
  par: Julia D’Agata Mount, et autres
  Publié: (2024)
• Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
  par: Payel J. Roy, et autres
  Publié: (2025)